U.S. Compounding Pharmacies Market Size, Share and Trends 2026 to 2035

What is the U.S. Compounding Pharmacies Market Size in 2026?

The U.S. compounding pharmacies market size is calculated at USD 6.45 billion in 2025 and is predicted to increase from USD 6.82 billion in 2026 to approximately USD 11.52 billion by 2035, expanding at a CAGR of 5.97% from 2026 to 2035. The market is driven by the rising trend of patient preference for customized drug dosages and cost-effective drug alternatives.

Market Highlights

• By Product, the oral medications segment dominated the market with the largest market share of 36.21% in 2025.
• By Pharmacy Type, 503A segment accounted for more than 72.99% of revenue share in 2025.
• By Sterility, the non-sterile segment dominated the market with the highest revenue of 71.97% in 2025.
• By Application, the adult segment is expected to significantly boost during the anticipated timeframe.

What are U.S. Compounding Pharmacies?

The U.S. compounding pharmacies market is slowly but steadily increasing with an impressive rate of growth and is showing no signs of slowing down. Much of this growth is propelled by the increasing demand for personalized medicine, meaning that each medication is individually tailored for each patient. Compounded medications are, by definition, not pre-manufactured drug products. Compounded medications are products prepared by pharmacists to meet an individual's specific needs, changing strength of dosing, altering route of administration, omitting allergens or unnecessary excipients, or combining active ingredients into one product.

Personalized approaches to health care are necessary in specialty areas such as pain syndromes, dermatology, hormone replacement therapy (HRT), pediatrics, and oncology where standard medications do not provide the best opportunity for success. Compounded solutions fill an essential gap that commercial drugs leave behind as the burden of chronic disease and polypharmacy issues continue to rise.

What are the Upcoming Trends in Compounding Pharmacies Market?

The increasing demand for integrative and functional medicine that embraces personalized, holistic care creates sustained demand for compounded medications in hospital and specialty clinics and wellness-focused pharmacies. Healthcare practitioners and patients are more aware of the clinical flexibility and therapeutic indications of compounded medications, which provides market entrenchment and increased acceptance. Coupled with ongoing trust and technological advances involving pharmacy automation and reducing the regulatory fog, compounding medication will continue to support and advance the fabric of healthcare delivery in the U.S.

How is AI-driven Technology Revolutionizing U.S. Compounding Pharmacies?

The U.S. compounding pharmacies market is evolving rapidly, and artificial intelligence is making an impact on precision, efficiency and safety in compounding processes. AI-enhanced pharmacy technology is allowing pharmacists to generated highly customized medications to patients, given an analysis of a patient's data, history and potential drug interactions. This improves personalized medication accuracy and overall therapeutic outcomes.

At the same time, robots and AI-enabled automation technologies found within sterile compounding labs can supplement fast and efficient workflows, resulting in greater degrees of precision, while also reducing human errors, contamination potential, and even turn-around times. Predictive analytics also help with managing stocks, projecting medication needs, and eliminating drug waste in navigating challenges between distribution chains and drug shortages. AI can allow the management to remain in compliance by automating and analysing patient documentation, and quality assurance processes as part of ongoing declarations that need to be submitted.

U.S. Compounding Pharmacies Market Growth Factors

• Growing Demand for Personalized Medicine: There is an increasing demand for personalized medicines, particularly in the form of individualized patient medicines, which can involve modifying the dosage form, adding a flavouring agent, or changing the dose. In countries such as California, Texas, and Florida, precision medicine plays a key role in the healthcare offerings and personalized care practices.
• Rising Burden of Chronic Diseases: The increasing incidence of chronic diseases such as diabetes, cardiovascular disease, hormonal imbalances, and cancer in the U.S. is greatly attributed to the increased need for compounding of medication. The use of personalized therapies improves the chances of treatment adherence and effectiveness.
• Increasing Use of Telehealth/Digital Healthcare Platforms: The use of telehealth/online compounding services is expanding and impacting access to compounded prescriptions. Cooperative projects between licensed compounding pharmacies and telehealth have shared numerous custom-made medicines to treat chronic conditions that began to expand across the country.
• Rising Demand for Hormone Replacement and Wellness Therapies: As awareness of health issues among hormones and preventive care increases, compounded hormone replacement and personalized medication for wellness is becoming increasingly popular. More people are looking for bioidentical hormones and customized nutritional supplements in these special environments.
• Regulatory Oversight and Quality Standards: Regulatory bodies such as the FDA and state pharmacy boards are making compounding subject to a greater degree of regulatory rigor than ever before to ensure that patients receive safe products. As the number of safety conditions and consumer confidence grow, so does the amount of investment in quality assurance, sterile-sounding production processes, and compliance systems.
• Advanced Compounding Technologies: Better efficiency, safety, and product customization aspects are being realized by investments in automation and sterile preparation systems. Technological advancements in compounding pharmacies can provide accurate dosages, prevent contamination, and enhance the quality of medicines

Major Trends of the U.S. Compounding Pharmacies Market

• Automation-Driven Precision in Compounding Operations: The adoption of automated and semi-automated equipment in compounding pharmacies is becoming more widespread as they strive for greater formulation accuracy, to minimize contamination risks, and to comply with stricter regulations, particularly in sterile settings.
• Growth of Veterinary/ Specialty Care Compounding: As more pet owners become active in their pet's health care decisions and create a need for customized veterinary medications, compounding pharmacies will continue to expand into the animal therapeutic market as well as the human therapeutic market.
• Integration with Provider-Centric Care Models: To create seamless continuity of care for patients who require non-commercial or alternative dosage forms, hospitals, clinics, and outpatient facilities are increasing their partnership efforts with compounding pharmacies.
• Shift Toward Using Digital Workflow and Compliance Platforms: Pharmacies are turning to tools such as digital intake for prescriptions, batch tracking, quality audit, and patient documentation systems, which allow the pharmacy to maintain traceability and transparency related to regulatory compliance.
• Supply Chain Resilience/API Sourcing Strategy: To protect against supply chain disruption while still obtaining high-quality active pharmaceutical ingredients (APIs) at a reasonable price, compounding pharmacies are diversifying their sources for APIs.

U.S. Compounding Pharmacies Market-Trade Analysis

• Orienting Toward Domestic Markets: Because of rigorous legal and regulatory oversight, alongside patient-specific manufacturing capabilities, the U.S. compounded pharmacy industry predominantly focuses on domestic production rather than exporting finished goods.
• Exports of Finished Compounded Medicines do not Come from the United States: The U.S. compounded pharmacy industry does not export finished compounded medicines (finished medications); however, it does import the component parts (active pharmaceutical ingredients), making it vulnerable to changes in regulations and quality standards for the ingredients used to formulate compounded pharmacy preparations.
• Distribution is Affected by the Federal and State Legal and Regulatory Environment: Several federal and state legal and regulatory restrictions limit the interstate distribution of certain compounded pharmacy products. This limitation promotes localized manufacturing and has a major impact in defining how procurement and logistics strategies are developed across different geographical areas.

Market Outlook

• Industry Growth Overview: The U.S. compounding pharmacies market is growing, as increasing demand for targeted medicine, the requirement to address drug limitations, and the prevalence of chronic diseases. The demand for modified medications to meet particular patient needs involves dosage, form, and allergen-free options.
• Global Expansion: The U.S. compounding pharmacies market is experiencing global expansion, as the growing presence of pharmacies that create customized medications beyond what is commercially available, driven by factors such as targeted medicine trends. North America is dominated by a mature medical infrastructure and highly targeted medicine.
• Major investors: Major investors in compounding pharmacies are often private equity organizations and other massive institutional investors attracted to the sector's growth and profitability. Particular organizations that are major players in the compounding pharmacy market include Fagron, PharMEDium, and TruMont Compounding Pharmacy.

Market Scope

Market Dynamics

Drivers

Rising Emphasis over Personalized Therapeutics

The growing demand for personalized therapeutics represents a significant opportunity in the compounding pharmacy marketplace across several niche areas including pediatric dosing, veterinary compounding, hormone optimization, and dermatological applications. Patients and providers (prescribers) are recognizing and requesting customized formulations that meet their unique needs, allergies, and dosing where appropriate, leading to a shift away from traditional one-size-fits-all pharmaceuticals to adopting precision-based care.

Advanced Technologies

With automation, automated compounding systems driven by AI, and robotics, pharmacies can provide scalable, sterile medications of high-quality, and with more accurate and consistent outcomes now more than ever. Collaborations with telehealth partners, concierge medicine organizations, and specialty clinics are allowing access to patients and channeling new ways for compounding pharmacy organizations to acquire new patients outside their geography.

These collaborations are especially relevant when utilizing telehealth services to get medications or customized formulations that do not exist during the ongoing national shortage of pharmaceuticals, which can keep compounding pharmacies relevant to current patient care provision. Digital transformations (e-commerce websites, online consultations, and apps) that provide a more convenient, compliant, and accessible way in providing customized formulations is catering to patients' needs.

Restraint

Stringent Regulatory Framework and High Cost:

Increased compliance costs and burdensome regulatory frameworks related to evolving FDA and USP guidance will continue to constrain U.S. compounding pharmacies operationally and financially. Compliance with these stringent standards, especially the sterile compounding requirements, constantly require investment in improvements to the facility and ongoing staff training and documentation, and adds overhead for smaller pharmacies and limits their scaling ability.

Quality control challenges only bring a higher risk of liability in a market with products that have to meet absolute sterility and exacting specifications, like injectables or ophthalmic products. And with inflexible reimbursement and ambiguous insurance coverage limiting profitability, it is challenging for providers to justify offering a compounded alternative to a mass-produced pharmaceutical. Providers often shift the financial risk of a compounded medication back to the patient because of the lack of consistent reimbursement, which is a primary impediment to wide-scale utilization. With emerging competition from large pharmaceutical manufacturing releasing pre-formulated drugs aimed at previously compounded only indications, the market pressure is only adding constraints.

Opportunity

Automation & Business Activities

There are opportunities for automation, and AI-based precision to drive scalable opportunities with fewer errors and improved quality. Through strategic partnerships with telehealth provider and specialty clinics we can access new patients. Supporting gaps in therapeutic options may be another growth path as we're back into drug shortages. The future is digital, and through e-commerce we can create digital options and access that improves patient access, as well as further streamline the prescription workload across the U.S.

Segment insights

Product Insights

The Oral Segment Dominated the U.S. Compounding Pharmacies Market in 2025

The oral segment held the largest market share in 2025, owing to the high preference of patients to get a convenient and easy-to-administer drug. Oral compounded formulations (capsules, tablets, powder, or granules, etc.) and some customized formulations are appropriate for the treatment of chronic diseases. These are formulated in varying proportions and flavors, and can be adapted as required to changes in ingredients, and are safe for children and the elderly.

The liquid preparations segment is expected to grow with the highest CAGR of XX% in the market during the studied years, as flexible formats of medicines are expected to be in demand. Liquid formulations are useful for patients who may be unable to swallow capsules and tablets, such as children, the elderly, and dysphagic patients. Compounding pharmacies can make customized medications with different concentrations and different flavors to promote adherence.

Pharmacy Type Insights

How Did the 503A Segment Lead the U.S. Compounding Pharmacies Market?

The 503A segment led the market in 2025 due to the need for personalized medicine according to the patient's requirements. With the increasing prevalence of chronic diseases and the development of knowledge about precision medicine. 503A pharmacies are becoming pivotal in the domain of healthcare to tackle challenges regarding therapeutic needs and adherence to medicine.

The 503B segment is expected to grow at the fastest CAGR during the forecast period due to the growing demand for compounded medicines on a large scale in hospitals and health care centers. They are drug manufacturing units that meet regulations for drug safety and quality, but can be outsourced to produce bulk, non-patient-specific drugs. The concern over drug shortages, rise in hospitalizations, and increased demand for sterile medicines in critical care settings.

U.S. Compounding Pharmacies Market Revenue, By Pharmacy Type, 2022-2024 (USD Billion)

Sterility Insights

Sterile Segment Held the Largest Share of the Market in 2025

The sterile segment held the largest share of the U.S. compounding pharmacies market in 2025, driven by rising demand for highly specialised drugs. The sterile compounding environment requires safety measures, including specially trained personnel, controlled environments, and high-tech safety measures. The growing size of sterile hospital admissions, the higher incidence of chronic diseases, and the higher stakes attached to norms of patient safety.

The non-sterile segment is anticipated to grow at a significant rate during the forecast period due to the growing adoption of customised medicines for regular health care treatments. The preparation, mixing, dilution, or modification of a product to facilitate its administration to a patient is referred to as non-sterile compounding. The customisation of healthcare solutions, offered by unique customisations of products for the dermatology, pain management, paediatric, and hormone replacement segments.

U.S. Compounding Pharmacies Market Revenue, By Sterility, 2022-2024 (USD Billion)

Therapeutic Area Insights

The Pain Management Segment Held the Largest Market Share in 2025

The pain management segment held the largest market share in 2025. A dosage formula designed by the pharmacy to meet a specific patient's requirements, such as an alternative dosage, a topical cream, or an allergy-free product. Consumers with arthritis, neuropathy, and fibromyalgia, as well as post-surgical pain, are seeking to treat their pain more effectively with the added benefit of customization.

The hormone replacement therapy segment is expected to witness the fastest growth in the market over the forecast period, as the awareness of the significance of hormone health and concern about ageing is expected to increase. Menohormone is being increasingly used in a customised formula to cure various menopausal symptoms, as well as thyroid hormone issues. Personalised dosage and delivery via compounding pharmacies enhance the effectiveness of treatment and patients' comfort.

U.S. Compounding Pharmacies Market Revenue, By Therapeutic Area, 2022-2024 (USD Billion)

End-user Insights

The Hospitals and Clinics Segment Dominated the Market in 2025

The hospitals and clinics segment contributed the biggest U.S. compounding pharmacies market share in 2025, driven by the increased demand for customized medications for inpatients and outpatients. Medication that is prepared for use on the hospital lines in critical care, pain management, pediatrics, oncology, and is specially compounded for a single patient. There is a rise in dependence on steroids, a rise in hospitalization rate, and a growing influence of chronic diseases.

The specialty clinics segment is expected to gain the highest market share between 2026 and 2035, due to the rising demand for single treatments for particular diseases. In recent years, compounded preparations have become a part of specialty clinics in the fields of dermatology, hormone replacement therapy, fertility, pain relief, and chronic disease care. Specialty clinics tailor compounded drugs for dosage, method of delivery, and allergy-friendly options without using dangerous ingredients.

Country Analysis

With an infrastructure that supports advanced healthcare, high demand for personalized medicine, and patient-centred care, the U.S. is the global leader in the compounding pharmacies market. The growing aging population and the increase in chronic disease conditions in the United States had increased the need for customized medications that mass-produced medications traditionally do not accommodate. Compounding pharmacies in the United States are increasingly providing compounded medications associated with specific patient needs through not reuse allergen medications, delivering medications in a manageable dosing while providing patient-specific medications that are not commercially manufactured.

It is estimated that states like Texas, California, and Florida will continue to be critical operations bases for advancing compounding pharmacies due to the volume of specialty clinics, their aging population and supportive regulators. Advances associated with artificial intelligence and automation in the compounding pharmacy industry are also a benefit to improve accuracy, sterility, and efficiency in operations. Furthermore, the growing use of and awareness associated with functional medicine, hormone replacement therapies, and alternative treatment options also reverberant the increased use of compounding pharmacy services.

Increasing digital technology

The U.S. is the fastest-growing market region because of its focus on personalized medicine, a complex yet supportive regulatory environment, ongoing drug shortages in the commercial sector, and a robust healthcare infrastructure. The increasing and aging population, which has a high rate of chronic conditions such as pain management needs and hormonal imbalances, fuels the demand for customized, long-term treatments that mass-produced drugs often cannot fully meet.

Value Chain Analysis – U.S. Compounding Pharmacies

R&D:

Major R&D process focuses on preparation, formulation, and quality control under particular government guidelines, rather than the extensive clinical trials for new drugs.

• Key Players: Fagron, B., and Braun Melsungen AG

Clinical Trials:

Major clinical trials include Phase 1 (safety), Phase 2 (effectiveness), Phase 3 (efficacy), and Phase 4 (long-term effects) trials.

• Key Players: Fresenius Kabi and Baxter International

Patient Services:

Major patient services at a compounding pharmacy include personalized medication creation, creating alternate dosage forms such as liquids or creams, adjusting strengths, and eliminating allergens from medications.

• Key Players: Empower Pharmacy and Dougherty's Holdings, Inc.

Competitive Landscape

The U.S. compounding pharmacies market is highly competitive, with campaigns continuing to be issued by the government to promote the use of tailored medications to the needs of an individual, and there is an increasing trend towards customized solutions of treatment. Established organizations such as Dougherty's Pharmacy, B. Braun, Harrow, Baxa International, Empower Pharmacy, and Fresenius Kabi are investing in the quality improvement program. For instance, Empower Pharmacy was recognized on the Inc. 5000 list of fastest-growing U.S. companies due to spending on infrastructure and technology to expand its customer base and offerings of personalised medications.

Their market positions are strengthened and expanded distribution networks throughout the country by making strategic acquisitions, working together, and building capacity. Investing in high-tech manufacturing technologies to meet the rigorous FDA requirements, new technologies, automation, and quality systems.

Top Vendors in the U.S. Compounding Pharmacies Market & Their Offerings

Other Major Key Players

• US Compounding Inc.
• Avella specialty pharmacy
• Institutional pharmacy solutions, llc
• Pharmedium services llc
• Vertisis custom pharmacy

Recent Developments

• In February 2025, Fagron launched an advanced software platform designed to streamline 503A workflows and track patient outcomes. (Source- https://fagron.com)
• In March 2025, Empower Pharmacy commenced operations at its second high-capacity 503B outsourcing facility in Houston, enhancing sterile compounding through automated and robotic systems. (Source- https://www.empowerpharmacy.com)
• In April 2025, the FDA clarified enforcement timelines for compounded GLP 1 drugs like semaglutide and tirzepatide, mandating phase-outs by April 22 and May 22 to align with finished product availability. (Source- https://www.fda.gov)

Segments Covered in the Report

By Pharmacy Type

• 503A
• 503B

By Product

• Oral
  • Capsules
  • Granules
  • Tablets
  • Powder
  • Others
• Liquid Preparations
  • Emulsion
  • Syrup
  • Solutions
  • Suspension
  • Others
• Topical
  • Gels
  • Ointments
  • Creams
  • Pastes
  • Others
• Rectal
  • Enema
  • Suppositories
  • Others
• Ophthalmic
• Nasal
• Otic

By Sterility

• Sterile
• Non-Sterile

By Compounding Type

• Pharmaceutical Ingredient Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)
• Others

By Therapeutic Area

• Hormone Replacement
• Pain Management
• Dermatology
• Pediatrics
• Urology
• Others

By End-User

• Hospitals and Clinics
• Specialty Clinics
• Others